An estimated 103,000 people die in the U.S. each year from Hospital Acquired Infections (HAI), as many deaths as from AIDS, breast cancer and auto accidents combined. The economic costs of Hospital Acquired Infections (also called nosocomial infections) are reported to be in excess of $38 billion annually in the United States. Managing bacteria (the breeding ground for infections) is one of the most effective ways of controlling infections.
The HyGenesis System for infection inhibition is the foundation of our growing solution set. The system includes three elements: 1) a unique product set which demonstrate long term efficacy after application, 2) specialized application techniques, and 3) a methodology for regular assessment and identification of bacterial burden. The system is extremely effective at attacking the breeding ground of antibiotic resistant - super bugs - such as Methicillin Resistant Staphylococcus Aureus (MRSA - 99.9%) and Vancomycin Resistant Enterococcus (VRE - 99.9%).
To reduce infection rates in hospitals, extended care facilities and schools
by developing and applying highly effective prophylactic technologies
that inhibit the root causes of dangerous infections.
By treating these root causes, HyGenesis can help healthcare providers significantly reduce post admission infection rates saving individual healthcare providers millions of dollars and thousands of lives while improving the overall health of the world community. In essence, HyGenesis attacks the root causes for the spread of infections as opposed to simply treating symptoms after infections have been contracted.
Current disinfection methods used by healthcare institutions have not significantly reduced the incidence of HAI due in large part to the fact that they do not have long-term inhibition characteristics. Long-term efficacy, with just a single application, is a critical element of the HyGenesis System and is a significant reason why it can replace existing disinfecting technologies with up to 30% savings.
The HyGenesis System has been developed in conjunction with assistance from renown healthcare and medical school researchers, chemists and scientists. We are actively taking our expertise in bacterial inhibition and infection protection into healthcare (i.e. hospitals, nursing homes, extended care facilities, etc.) and schools as well as other market segments interested in improving the overall health of their communities.